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The inositol pyrophosphate IP7 (5-diphosphoinosi-
tolpentakisphosphate), formed by a family of three
inositol hexakisphosphate kinases (IP6Ks), modu-
lates diverse cellular activities. We now report that
IP7 is a physiologic inhibitor of Akt, a serine/threo-
nine kinase that regulates glucose homeostasis and
protein translation, respectively, via the GSK3b and
mTOR pathways. Thus, Akt and mTOR signaling
are dramatically augmented and GSK3b signaling
reduced in skeletal muscle, white adipose tissue,
and liver of mice with targeted deletion of IP6K1.
IP7 affects this pathway by potently inhibiting the
PDK1 phosphorylation of Akt, preventing its activa-
tion and thereby affecting insulin signaling. IP6K1
knockout mice manifest insulin sensitivity and are
resistant to obesity elicited by high-fat diet or aging.
Inhibition of IP6K1 may afford a therapeutic ap-
proach to obesity and diabetes.INTRODUCTION
Inositol phosphates are widely distributed in animal and plant
tissues. Most studied is inositol 1,4,5-trisphosphate (IP3), which
releases calcium from intracellular stores (Berridge et al., 2000;
Irvine and Schell, 2001). More recently, higher inositol phos-
phates with energetic pyrophosphate bonds have been de-
scribed (Shears, 2007), which are synthesized by a family of
three IP6 kinases (IP6Ks) (Saiardi et al., 1999; Saiardi et al.,
2001). Best characterized is diphosphoinositol pentakisphos-
phate (5-PP-[1,2,3,4,6]IP5), here designated IP7 (Barker et al.,
2009). In mammals, IP7 modulates numerous physiologic func-
tions, including apoptosis (Chakraborty et al., 2008; Koldobskiy
et al., 2010) and insulin secretion (Illies et al., 2007), whereas,
in budding yeast, it influences endocytosis (Saiardi et al., 2002)and telomere length (Saiardi et al., 2005; York et al., 2005)
maintenance. Another isoform of IP7, identified as 1/3-PP-IP5,
is formed by the Vip1 enzyme (Lin et al., 2009; Mulugu et al.,
2007) and in yeast influences cell shape, growth, and phosphate
disposition (Lee et al., 2007).
IP6K1 depletion by RNA interference impairs insulin secretion
by pancreatic b cells (Illies et al., 2007), and IP6K1 KO mice
manifest reduced circulating insulin levels (Bhandari et al.,
2008). Despite low serum insulin, IP6K1-deleted (IP6K1 KO)
mice display normal blood glucose levels and tolerance,
implying insulin hypersensitivity (Bhandari et al., 2008).
IP7 can signal by physiologically pyrophosphorylating protein
targets (Bhandari et al., 2007; Saiardi et al., 2004). In yeast,
1/3-PP-IP5 binds the cyclin-cdk complex to regulate phosphate
metabolism (Lee et al., 2007).
Pleckstrin homology domains (PH domains) (Lemmon, 2008)
bind phospholipids such as phosphatidylinositol(3,4,5)-trisphos-
phate (PIP3) and phosphatidylinositol (4,5)-bisphosphate (PIP2)
(Di Paolo and De Camilli, 2006; Fruman et al., 1999), thereby
recruiting signaling proteins to membranes. IP7 interferes with
the binding of PIP3 to the PH domain of the Dictyostelium-
specific cytosolic regulator of adenylyl cyclase (CRAC) to inhibit
chemotaxis (Luo et al., 2003).
Akt (PKB), a PH domain containing serine/threonine kinase,
regulates growth factor signaling (Chan et al., 1999; Cho et al.,
2001; Taniguchi et al., 2006) to stimulate glucose uptake (Welsh
et al., 2005), glycogen synthesis (Cross et al., 1995), and protein
synthesis (Memmott and Dennis, 2009; Ruggero and Sonen-
berg, 2005) by influencing glucose transporter 4 (GLUT4),
glycogen synthase kinase 3 (GSK3)a/b, and tuberous sclerosis
complex 2 (TSC2)-mTOR signaling pathways.
Increased protein translation following Akt activation elicits
skeletal muscle hypertrophy (Rommel et al., 2001) and augments
hepatic fatty acid oxidation with reduced fat accumulation (Izu-
miya et al., 2008). GSK3b, which influences insulin resistance,
is phosphorylated and inhibited by Akt (Cross et al., 1995). Akt
and GSK3b activity are reciprocally regulated in insulin resis-
tance and obesity. Akt/mTOR activity is decreased (FunaiCell 143, 897–910, December 10, 2010 ª2010 Elsevier Inc. 897
Figure 1. Growth Factor-Induced IP7 Regulates Akt Activity
(A) IGF-1 treatment enhances intracellular IP7 levels in WT, but not in IP6K1 KO, MEFs.
(B) IP6K1 KO MEFs exhibit increased phosphorylation of Akt and Akt/mTOR downstream targets GSK3b, TSC2 S6K1, and S6 after 15 min IGF-1 treatment.
Tyrosine phosphorylation of IGF-1-induced upstream PI3 kinase activator IRS1 and PDK1 target PKCz is unchanged.
(C) Densitometric analysis displays3-fold and1.75-fold enhancement, respectively, in T308 and S473 Akt phosphorylation of IP6K1 KOMEFs following IGF-1
treatment.
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et al., 2006; Shao et al., 2000) and GSK3b increased (Kaidano-
vich and Eldar-Finkelman, 2002) in insulin-resistant tissues of
aging and obese mice.
The apparent insulin sensitivity of the IP6K1 KO mice promp-
ted our interest in IP7 regulation of Akt and insulin signaling.
We now show that IP7 is a physiologic inhibitor of Akt signaling,
acting at the enzyme’s PH domain to block phosphorylation and
activation by PDK1. Thus, IP6K1 KO mice display a very marked
enhancement of Akt activity accompanied by augmented insulin
sensitivity and resistance to weight gain.
RESULTS
Growth Factor-Induced IP7 Formation Inhibits Akt
Signaling
Wemonitored IP7 formation of serum-starved MEFs in response
to IGF-1 (Figure 1A and Figure S1A available online). In WT
MEFs, serum starvation decreases IP7 formation more than
90%, whereas IGF-1 rapidly restores IP7 levels with complete
restoration toWT values by 60min. The stimulation of IP7 forma-
tion by IGF-1 is abolished in IP6K1-deleted MEFs. In WT MEFs,
serum deprivation reduces levels of IP6 much less than IP7, and
IGF-1 enhances formation of IP6much less than IP7 (Figure S1B).
In hepatocellular carcinoma cell line HEPG2, insulin or IGF-1
treatment similarly stimulates IP7 formation (Figure S1C).
Akt is activated by phosphorylation at T308 by PDK1 and at
S473 by mTOR (Alessi et al., 1997; Sarbassov et al., 2005).
IP6K1 KO MEFs display markedly augmented IGF-1-stimulated
phosphorylation of Akt (T308/S473) (Figures 1B and 1C) without
any alteration in tyrosine phosphorylation of insulin receptor
substrate 1 (IRS-1), an upstream activator of PI3 kinase. We
also observe increased phosphorylation of Akt downstream
effectors GSK3b (S9), TSC2 (T1462), S6K1 (T389), and S6
(S235/S236) in response to IGF-1 (Figure 1B).We detect similarly
increased growth factor-mediated signaling in a separate clone
of IP6K1 KOMEFs (Figure S1D). To assess specificity, we moni-
tored an atypical PKC, PKCz, which is a PH domain-deficient
PDK1 target (Figure 1B). PKCz phosphorylation levels are the
same in IP6K1-deleted andWTMEFs in the absence or presence
of IGF-1. Phosphorylation of the growth factor-stimulated kinase
ERK and the PDK1 target PKCD are also unchanged (Fig-
ure S1D). Akt can be activated via a variety of mechanisms,
especially those involving PI3 kinase and its generation of PIP3(D) Increased activation in IP6K1 KOMEFs is not due to elevated PI3 kinase signa
and after 15 min IGF-1 treatment.
(E) IP6K1 is a primary source of IP7 synthesis in the liver. Primary hepatocytes is
levels.
(F) Primary hepatocytes of 10-month-old IP6K1 KO mice after insulin treatmen
phosphorylation status of PDK1 targets PKCz and PKCD.
(G) Densitometry reveals 5-fold and 2-fold enhancement, respectively, in T30
insulin treatment for 30 min.
(H) Complementation of IP6K1-WT, but not IP6K1-K/A, restores physiological le
(I) Complementation of IP6K1 KOMEFs with IP6K1-WT reduces phosphorylation
and S636/639 phosphorylation of upstream PI3 kinase activator IRS1 are unalte
(J) IP6K1-WT complementation elicits 3-fold reduction in IGF-1-induced T308
(K) Transient Myc-IP6K1 overexpression elicits decrease in IGF-1-dependent Ak
(L) Overexpression of IP6K1-WT reduces IGF-1-induced phosphorylation of T30
Each experiment was repeated at least three times. ***p < 0.001; **p < 0.01; and(Alessi et al., 1997). We evaluated the formation of PIP3 in WT
and IP6K1 KO MEFs (Figure 1D). Serum deprivation of WT
MEFs markedly decreases PIP3 formation, which is reversed
by treatment with IGF-1. The effects of serum deprivation
and IGF-1 treatment are the same in IP6K1-deleted as in WT
MEFs. We also measured PI3 kinase catalytic activity and tyro-
sine phosphorylation status of its p85 subunit, which are
unaltered in IP6K1 KO MEFs following IGF-1 treatment (Figures
S1E and S1F). Basal PI3 kinase activity in WT and IP6K1
KO MEFs is also unaltered (data not shown). Thus, IP6K1 regu-
lation of Akt is not due to alteration of PI3 kinase activity or
PIP3 levels.
To examine insulin signaling in IP6K1 KO liver, we isolated
primary hepatocytes, which display 60% reduction in IP7,
with unaltered levels of IP6 relative toWT hepatocytes (Figure 1E
and Figures S1G and S1H). IP6K1 KO hepatocytes manifest
elevated phosphorylation of Akt, GSK3b, and S6 in response
to insulin, with no alteration in p-PKCz/p-PKCD, other targets
of PDK1 (Figures 1F and 1G).
Complementation of IP6K1-WT, but not IP6K1-K/A (kinase
dead), restores physiological IP7 levels in IP6K1 KO MEFs (Fig-
ure 1H and Figures S1I and S1J). Levels of p-Akt (T308/S473)
and p-GSK3b are diminished in IGF-1-stimulated MEFs
expressing IP6K1-WT, but not in IP6K1-K/A clone (Figures 1I
and 1J). Growth factor signaling is inhibited by S6K1 via phos-
phorylation of IRS1 at S636/639 residues (Um et al., 2004). We
do not observe any change in phosphorylation status of IRS1
at S636/639 or at tyrosine residues (Figure 1I). We observe
similar effects in complemented MEFs induced with serum (Fig-
ure S1K). IP6K1-WT overexpression lowers Akt and GSK3b
phosphorylation levels in IGF-1-stimulated HEK293 cells (Fig-
ures 1K and 1L).
The enhancement in Akt/mTOR signaling is accompanied by
parallel changes in protein synthesis. Thus, IP6K1 KO MEFs
manifest a 15% increase in protein translation (Figure S1L).
Wortmannin and rapamycin each reducewild-type protein trans-
lation about 20%–25%, consistent with the Akt-mTOR pathway
accounting for only about 20%–25% of total protein synthesis
(Holz et al., 2005). The increased protein translation of IP6K1
KO MEFs is reduced by about 25% following overexpression
of IP6K1-WT, but not IP6K1-K/A (Figure S1M). To ascertain
whether IP6K1 regulates Akt/mTOR activation in intact organ-
isms, we monitored phosphorylation of ribosomal protein S6 inling. Intracellular PIP3 levels are similar in WT and IP6K1 KOMEFs under basal
olated from 10-month-old IP6K1 KO mice display 60% reduction in the IP7
t manifest enhanced phosphorylation of Akt, GSK3b, and S6, with unaltered
8 and S473 phosphorylation levels of Akt in IP6K1 KO hepatocytes following
vels of IP7 in the IP6K1 KO MEFs.
of Akt and GSK3b, with IP6K1-K/A having no effect. IGF-1-dependent tyrosine
red.
and S473 Akt phosphorylation. IP6K1-K/A does not have any effect.
t and GSK3b phosphorylation in HEK293 cells.
8 and S473 Akt to 3-fold, whereas IP6K1-K/A has much less effect.
*p < 0.05). See also Figure S1.
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Figure 2. IP7 Inhibits Akt T308 Phosphorylation and Membrane Translocation
(A) Immunofluorescence analysis of IGF-1-induced T308 phosphorylation andmembrane translocation of Akt in absence of IP6K1. IGF-1-treated IP6K1 KOMEFs
display enhanced T308 phosphorylation of Akt and augmented membrane translocation. Green and red represent total and p-T308 Akt, respectively, whereas
yellow is the merged color for total and p-T308 Akt.
(B–D) Western blot analysis demonstrates increased T308 phosphorylation and membrane localization of Akt in IP6K1 KO MEFs after IGF-1 treatment. We also
observe an increase in cytosolic p-T308 Akt levels in the IP6K1 KO MEFs.
(E) Complementation of IP6K1 KOMEFswith IP6K1-WT causes a delay in Akt translocation to the plasmamembrane, whereas IP6K1-K/A does not show this effect.
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the gastrocnemius muscle and liver of IP6K1 mutant mice and
observed a pronounced enhancement (Figure S1N). IP6K1 dele-
tion leads to decreased 4EBP1 binding to eIF4E (Holz et al.,
2005) at the mRNA cap in insulin-treated mice liver and gastroc-
nemius muscle (Figure S1O).
In summary, growth factor stimulation enhances IP7 forma-
tion, which in turn inhibits Akt signaling. Accordingly, marked
augmentation of Akt signaling is seen in IP6K1-deleted tissues.
IP7 Inhibits Akt T308 Phosphorylation
and Membrane Translocation
In response to growth factors, PIP3 stimulates Akt at the
membrane by facilitating its phosphorylation by PDK1 (Alessi
et al., 1997).Wemonitored IGF-1-dependentmembrane translo-
cation of Akt in MEFs of WT and IP6K1 KO mice (Figures 2A and
2B). We observe increased membrane localization of total Akt
and p-T308 Akt following IGF-1 treatment in IP6K1-deleted
MEFs (Figure 2A). Membrane levels of Akt protein are markedly
enhanced by IGF-1 in WT preparations, with the enhancement
increased in IP6K1 KO cells (Figures 2B and 2C). Membrane-
associated p-T308 Akt is also strikingly increased in IP6K1 KO
preparation, with some cytosolic increase as well, presumably
reflecting movement of phosphorylated Akt from membrane to
cytosol (Figure 2B). Complementation of IP6K1-WT markedly
reduces IGF-1-elicited membrane translocation of Akt. Vector
alone or kinase dead IP6K1 (IP6K1-K/A) does not reduce
membrane Akt (Figure 2E).
The IP6K inhibitor TNP (10 mM) (Padmanabhan et al., 2009)
increases the IGF-1-elicited stimulation of T308 phosphorylation
of Akt without influencing p-S473. (Figure S2A). The increased
Akt signaling elicited by TNP is not evident in IP6K1 null cells
(Figure S2B). TNP increases T308 Akt phosphorylation in both
membrane and cytosol fractions (Figure S2C).
PDK1-mediated phosphorylation of Akt is dramatically
increased by PIP3 binding to Akt’s PH domain via presumed
conformational alterations (Calleja et al., 2007). We examined
the influence of IP7 or IP6 upon PDK1-elicited phosphorylation
of Akt in the presence of PIP3 in vitro (Figures 2F and 2G). IP7
inhibits phosphorylation of Akt at T308 about 50% at 1 mM,
whereas IP6 does not. Of interest, the IC50 for IP7 inhibition
resembles the PIP3 concentration required for maximal activa-
tion. We observe the inhibitory effect only when IP7 and Akt
are preincubated together at the same time. When PIP3 is prein-
cubated with Akt prior to the addition of IP7, IP7’s IC50 increases
to 50 mM (data not shown), beyond its physiological range. This
observation also fits with the prior reports that IP7 failed to
release Akt prebound to PIP3 (Downes et al., 2005). Myristoyla-
tion anchors Akt to the plasma membrane and irreversibly
activates it (Andjelkovic et al., 1997). Thus, IP6K1-WT overex-
pression in HEK293 cells reduces T308 phosphorylation of
WT-Akt, but not of myristoylated Akt, upon growth factor stimu-
lation (data not shown).(F and G) PIP3-induced (1 mM) Akt-T308 phosphorylation is inhibited by IP7, wit
(H and I) IP7 inhibits PDK1-dependent Akt phosphorylation at T308 in vitro, with
(J) IP7 inhibition of PDK1-dependent phosphorylation of overexpressed Akt imm
phorylation in vitro, which is abolished by IP7. IP4 does not have any significant
Each experiment was repeated at least three times. ***p < 0.001; **p < 0.01; andIn the absence of added PIP3, IP7 is substantially more potent,
inhibiting PDK phosphorylation of Akt with an IC50 of about 20 nM
(Figures 2H and 2I). Phosphorylation of overexpressed Akt
immunoprecipitated from serum-starved HEK293 cells by PDK1
in vitro is abolished by 1 mM IP7, with IP4 having no effect (Fig-
ure 2J). The inhibitory action of IP7 is selective, with IP5 and IP6
exertingmuch less inhibitionand IP3and IP4 inactive (FigureS2D).
Because of the competition between IP7 and PIP3 for PH
domain binding (Luo et al., 2003), we presume that the inhibitory
effect of IP7 on Akt phosphorylation is primarily exerted via the
PH domain. IP7 fails to inhibit PDK phosphorylation of Akt lack-
ing its PH domain (Figure S2E). IP7 at 1 mM concentration does
not inhibit S6K1 catalytic activity on peptide substrates in vitro
(data not shown). IP7 binds to PDK1 (data not shown) but does
not affect its catalytic activity on artificial peptide substrates,
indicating that IP7 does not inhibit PDK1 activity in general (Fig-
ure S2F), consistent with an earlier report (Komander et al.,
2004). The PH domain of PDK1 occurs in the enzyme’s C
terminus and does not influence its catalytic activity.
We presume that IP7 regulates Akt by binding directly to its PH
domain. Previously, we demonstrated that IP7 potently and
selectively competes with PIP3 for binding to the PH domain of
Akt, as IP6 failed to inhibit binding except at very high concentra-
tions (Luo et al., 2003). In the present study, [3H]IP7 binds to full-
length Akt, with binding drastically reduced for Akt lacking the
PH domain (Figure S2G). IP7 does not affect mTORC2 activity
toward Akt-S473 in vitro (Figures S2H and S2I).
IP6K1-Deleted Mice Display Sustained Insulin
Sensitivity
Six-week-old IP6K1 KO mice displayed reduced blood levels of
insulin, with normal plasma glucose implying insulin hypersensi-
tivity (Bhandari et al., 2008). Age-induced insulin resistance is
associated with decreased Akt activity (Funai et al., 2006; Shay
and Hagen, 2009). Accordingly, we explored insulin sensitivity
in terms of blood glucose levels in 10-month-old mice (Figure 3A
and 3B). These mice display significantly improved glucose
tolerance following glucose infusion (Figure 3A). Following insulin
administration, the IP6K1 KO mice display significantly lower
blood levels of glucose than doWTmice (Figure 3B), establishing
that older IP6K1 knockouts are indeed hypersensitive to insulin.
Increased insulin sensitivity should be associated with im-
proved glucose uptake from plasma. To evaluate glucose utiliza-
tion, we employed hyperinsulinemic-euglycemic clamp studies
(Figure 3C). The insulin sensitivity of the IP6K1 KO is more than
double that of WT mice. We monitored the uptake of glucose
into muscle and fat tissue in the clamp experiments (Figure 3D).
In gastrocnemius muscle and epididymal white adipose tissues
(EWAT), glucose uptake is approximately tripled in the mutant
mice. We do not observe any significant change in liver glucose
uptake (data not shown), presumably because uptake is largely
mediated by GLUT4 in muscle and adipose tissue.h an IC50 of 1 mM in vitro.
an IC50 value of 20 nM.
unoprecipitated from serum-starved HEK293 cells. PDK1 increases Akt phos-
effect.
*p < 0.05. See also Figure S2.
Cell 143, 897–910, December 10, 2010 ª2010 Elsevier Inc. 901
Figure 3. IP6K1 KO Mice Manifest Sustained Insulin Sensitivity
(A) Glucose tolerance test (GTT). IP6K1 KO mice display improved glucose tolerance than WT (male, n = 5, each set).
(B) Insulin tolerance test (ITT). In response to insulin, IP6K1 KO mice display a greater glucose removal rate than WT littermates (male, n = 5, each set).
(C) Hyperinsulinemic-euglycemic clamp studies. Glucose infusion rates (GIR) display 3-fold increase in IP6K1 KO mice than WT littermates (male, n = 4,
each set).
(D) Glucose uptake in gastrocnemius muscle and in epididymal white adipose tissue (WAT) is significantly enhanced in IP6K1 KO mice (male, n = 4, each set).
(E) Acute insulin sensitivity in IP6K1 KO mice. Insulin treatment causes enhanced p-Akt and p-GSK3b levels downstream of IRS-1 phosphorylation in the
gastrocnemius muscles of IP6K1 KO mice.
(F) Acute insulin treatment leads to 2-, 2.5-, and 4-fold increase in phosphorylation status of T308, S473 of Akt, and S9 of GSKb, respectively.
(G) Increased glycogen content in gastrocnemius muscle of IP6K1 KO mice after 30 min insulin treatment of 16 hr fasted mice (n = 3, each set).
(H) IP7 levels in young and old hepatocytes. IP7 levels increase significantly with age in the WT mice (n = 3, each set).
***p < 0.001; **p < 0.01; and *p < 0.05. See also Figure S3.We monitored Akt signaling in response to acute insulin treat-
ment (Figures 3E and 3F). In gastrocnemius muscle, levels of
p-Akt (T308/S473) are markedly increased in IP6K1 KO mice,
as are levels of the Akt downstream target p-GSK3b. On the
other hand, insulin receptor substrate (IRS1) phosphorylation is
similar in KO and WT mice, indicating that the insulin sensitivity
is due to regulation of Akt/GSK3b downstream of IRS1. We do
not observe any alteration in S6K1-mediated inhibitory phos-
phorylation of S636/S639 IRS1 under these conditions (data
not shown). Increased insulin sensitivity is also observed in902 Cell 143, 897–910, December 10, 2010 ª2010 Elsevier Inc.epididymal white adipose tissue (EWAT) of IP6K1 KO mice (Fig-
ure S3A). We detect enhancement in insulin-mediated glycogen
formation in the gastrocnemius muscle of IP6K1 KO mice
(Figure 3G).
To explore relationships between age-dependent Akt activity
and IP7 levels, we measured inositol phosphates in 2- and
10-month-old mice (Figure 3H and Figures S3B and S3C).
Both IP6 and IP7 levels are elevated in the older mice, with
greater augmentation in IP7, resulting in increased IP7/IP6 ratios.
The knockout hepatocyte preparations display an enhancement
in age-dependent increase in p-T308 Akt, suggesting that
increases in IP7 levels with age interfere with Akt activation
(Figures S3D and S3E).
In summary, in WT animals, age-dependent increases in IP7
formation accompany decreased insulin sensitivity, which may
explain the increased insulin sensitivity in aged IP6K1 KO mice.
IP6K1 KO Mice Are Resistant to Obesity
IP6K1 knockout mice exhibit reduced body weight (Bhandari
et al., 2008), which is more prominent with age (Figure 4A). The
reduced body weight primarily reflects reduced fat accumulation
with decreased weight of epididymal adipose tissue (EWAT)
(Figure 4B) as well as diminished weights of other visceral and
subcutaneous fat (data not shown). Despite lower body weight,
IP6K1 KO mice display increased gastrocnemius muscle mass
(Figure S4A). These findings may be consistent with earlier
observations (Izumiya et al., 2008) that increased Akt signaling
leads to muscle hypertrophy, enhanced insulin sensitivity, and
resistance to HFD-induced weight gain.
We examined body weight of IP6K1 KO mice under high-fat
diet (HFD) conditions. Six-week-old IP6K1 KO mice on control
diet (CD) are slightly smaller than WT littermates (Figures 4C,
4E, and 4F, orange and brown circles). However, when exposed
to HFD, they display striking resistance to body weight gain
(Figures 4D–4F, light and dark green triangles), with less than
one-third of WT weight gain. WT mice on HFD display a 300%
greater increase in body fat than IP6K1 KO mice (Figures 4G
and 4H and Figure S4B), as assessed by Echo-MRI analysis.
With or without HFD, IP6K1 KO mice display a markedly lower
weight of diverse fat pads with unchanged brown fat (BAT)
weight on control diet (Figure 4I).
Serum leptin levels are markedly lower in KO mice on CD or
HFD (Figure 4J), consistent with their reduced fat mass and
indicating increased leptin sensitivity (Myers et al., 2008).
The liver is the major organ responsible for metabolizing fat to
generate energy. Aberrations in the process lead to fatty liver
disease or hepatic steatosis (Reddy and Rao, 2006). IP6K1 KO
mice display resistance to high-fat diet-induced weight gain in
the liver (Figure 4K). Lipid droplets visible in the WT liver on
control or high-fat diet are absent in IP6K1 KO mice (Figure 4L
and Figure S4C). Thus, in the IP6K1 KO mice, resistance to
weight gain is due to reduced fat accumulation. High-fat diets
cause increases in serum triglycerides, cholesterols, aspartate
aminotransferase (AST), and lactate dehydrogenase (LDH)
(Hoffler et al., 2009; Ito et al., 2008). These substances are signif-
icantly lower in IP6K1 KO than WT mice (Figures S4D–S4G).
IP6K1 Deletion Improves Glucose Homeostasis
in High-Fat Diet-Fed Mice Associated
with Increased Akt Signaling
HFD-induced weight gain impairs insulin sensitivity and glucose
homeostasis (Kahn et al., 2006), whereas mice with insulin
hypersensitivity resist the sequelae of HFD (Elchebly et al.,
1999; Izumiya et al., 2008). After 8 weeks on HFD, IP6K1 KO
mice do not display the hyperglycemia evident in WT mice
(Figures 5A and 5B). HFD in WT mice leads to prolonged eleva-
tions in blood glucose levels following a glucose injection (Fig-
ure 5C and Figure S5). IP6K1 KO mice are protected from theimpaired glucose tolerance. Insulin tolerance tests (ITT) reveal
greater insulin-induced reductions of blood glucose in KO mice
on HFD, with no difference on regular diet (Figure 5D). Serum
insulin levels are significantly lower in IP6K1 KOs on regular
diet (Bhandari et al., 2008), which is even more striking after
high-fat exposure when the WT insulin levels reach pathologic
levels (Figure 5E). Under the same experimental conditions
described in Figure 5E, we measured Akt signaling in 4 hr fasted
mice (Figure 5F). HFD elicits higher levels of phosphorylated Akt,
GSK3b, and S6 in IP6K1 KO mice than in WT. The mutant mice
display similar insulin levels as WT mice on CD. Despite high
insulin levels, WT mice on HFD do not exhibit increased Akt
phosphorylation, consistent with insulin resistance. IP6K1 KO
mice are protected from HFD-induced insulin resistance. Thus,
IP6K1 KO mice do not display the HFD-induced insulin resis-
tance associated with reductions in Akt signaling.
IP7 Reduces Fat Breakdown and Enhances
Adipogenesis
Besides altering insulin sensitivity, Akt and its downstream effec-
tors can reduce fat accumulation by: (1) diminishing food intake
viamTOR (Cota et al., 2006), (2) increasing fat utilization or oxida-
tion via Akt (Izumiya et al., 2008), and (3) reducing adipogenesis
via GSK3b (Ross et al., 2000).
Food intake of IP6K1 KOs does not differ from WT on control
diet (Bhandari et al., 2008) or HFD (Figure 6A). WT mice on HFD
exhibit reduced oxygen consumption (VO2) and carbon dioxide
release (VCO2) (Figures 6B and 6C). We assessed energy expen-
diture (EE) based on both fat and lean body mass, as fat mass
also alters energy expenditure (Kaiyala et al., 2010). WT on
HFD display reduced EE, presumably reflecting locomotor hypo-
activity, similar to adipose tissue-specific PPARg knockout mice
(Jones et al., 2005; Tou and Wade, 2002) (Figure 6D). IP6K1 KO
mice on HFD are protected from reductions in VO2, VCO2, and
energy expenditure, resulting in an increase in energy expendi-
ture in the knockouts (Figure 6D). Respiratory quotient (RQ),
a reflection of carbohydrate and fat consumption, is decreased
to a similar extent in WT and IP6K1 KO mice (Figure 6E).
Increased fat oxidation in IP6K1 KO mice is confirmed by
switching mice from high-fat to control diet. The change in diet
elicits decreased body weight to a much greater extent in
IP6K1 mutants than in WT mice (Figures 6F and 6G). Plasma
ketone concentrations, which reflect hepatic fat oxidation, are
significantly increased in IP6K1 KO mice on both control and
high-fat diet (data not shown).
During adipogenic differentiation of NIH 3T3-L1 cells, IP7
levels rise and are substantially reduced by the IP6K inhibitor
TNP (Figure 6H and Figure S6A). IP6 levels are increased much
less and are unaffected by TNP (Figure S6B). GSK3b, inhibited
by Akt, inhibits adipogenesis (Ross et al., 2000). The GSK3b
inhibitor SB21676 inhibits differentiation of NIH 3T3-L1 cells
(Tang et al., 2005). We monitored differentiation of 3T3-L1
preadipocytes in the presence of IP6K and GSK3b inhibitors
(Figures 6I and 6J). SB216763 completely blocks 3T3-L1
differentiation at 10 mM, whereas 1 mM drug elicits minimal
effects. TNP (10 mM) inhibits differentiation 20%–25%. The
combination of TNP (10 mM) and SB216763 (1 mM) virtually
abolishes adipogenesis (Figures 6I and 6J). GSK3b facilitatesCell 143, 897–910, December 10, 2010 ª2010 Elsevier Inc. 903
Figure 4. IP6K1 KO Mice Are Resistant to Obesity
(A) IP6K1 KO mice display significant reduction in body weight compared to WT littermates at the age of 10 months (male, n = 5, each set).
(B) Reduced body weight in IP6K1 KO mice reflects less fat accumulation. Epididymal white adipose tissue (EWAT) weight is significantly less in 10-month-old
IP6K1 KO mice than WT littermates (male, n = 5, each set).
(C) Six-week-old WT and IP6K1 KO mice under control diet (CD) conditions.
(D) IP6K1 KOmice are resistant to weight gain following high-fat diet (HFD) exposure. Six-week-old IP6K1 KO and their WT littermates (males and females) were
exposed to HFD for 15 weeks.
(E and F) Time-dependent increase in body weight of IP6K1 KO and WT littermate males (E) and females (F) upon exposure to control and high-fat diet
(***p < 0.001, n = 8, each set).
(G and H) Echo-MRI analysis for body fat quantification in IP6K1 KO mice after 8 weeks of HFD exposure (male, n = 5, each set). IP6K1 KO mice display signif-
icantly less deposition of total fat (G) and percent fat/lean mass (H).
(I) Weights of epididymal (E), retroperitoneal (R), dorso-subcutaneous (D), inguinal (I) white adipose tissues (WAT), and brown adipose tissue (BAT) isolated from
WT and IP6K1 KO mice on CD and on HFD for 8 weeks (male, n = 3, each set). IP6K1 KO display reduced WAT mass under both diet conditions. BAT mass is
similar in mice on CD but is increased at a lower rate in the IP6K1 KO on HFD.
(J) IP6K1 KO mice display low serum leptin levels and are resistant to HFD-induced hyperleptinemia (male, n = 6, each set).
(K) IP6K1 KO mice are protected from high-fat diet-induced enhancement in liver weight (male, n = 3, each set). Mice were exposed to CD or HFD for 8 weeks.
(L) Oil red O staining of lipid droplets in the livers of WT and IP6K1 KO mice on CD or HFD. Magnification, 203; scale bar, 30 mM.
***p < 0.001; **p < 0.01; and *p < 0.05. See also Figure S4.
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Figure 5. IP6K1 Deletion Improves Glucose Homeo-
stasis under High-Fat Conditions
(A and B) IP6K1 KOmice are significantly resistant to hypergly-
cemia induced by 8 weeks exposure to HFD (male, n = 8,
each set).
(C) Glucose tolerance test (GTT) in mice after CD and HFD
exposure for 8 weeks (male, n = 5, each set). IP6K1 KO mice
on HFD display more efficient glucose removal from serum
than WT. Same aged IP6K1 KO and WT mice have similar
glucose tolerance on CD.
(D) Insulin tolerance test (ITT) at 8 weeks of CD or HFD expo-
sure in mice (male, n = 5, each set). In response to insulin,
IP6K1 KO mice display a greater glucose disposal rate than
WT littermates on HFD, with no difference on control diet.
(E) IP6K1 KOmice display reduced serum insulin under control
diet conditions and do not display the hyperinsulinemia of WT
mice at 8 weeks of HFD exposure (male, n = 6, each set).
(F) Representative western blot of 4 hr fasted IP6K1 KO mice
(as described in Figure 5E) do not display insulin resistance of
WTmice. Knockouts on HFD exhibit increased Akt signaling in
skeletal muscle.
***p < 0.001; **p < 0.01; and *p < 0.05. See also Figure S5.adipogenesis through enhanced expression of the adipogenic
transcription factor PPARg (Farmer, 2005). PPARg protein levels
decline with cotreatment of IP6K and GSK3b inhibitors and in
IP6K1 KO mice white adipose tissues (Figures S5C and S5D).
These observations indicate that reduced fat accumulation in
the IP6K1 KO mice is a result of sustained insulin sensitivity,
increased fatty acid oxidation, and reduced adipogenesis.
DISCUSSION
In summary, IP7 generation by IP6K1 is enhanced by insulin.
Moreover, IP7 is a physiologic inhibitor of Akt signaling, diminish-Cell 143, 8ing insulin sensitivity and protein translation via the
GSK3b and mTOR signaling pathways, which are
associated with insulin resistance and weight gain
(Figure 7). Insulin activation of Akt stimulates
protein translation as well as glucose uptake and
glycogen formation (Figure 7A). Aging or high-fat
diet increases IP7 levels, which interfere with Akt
activation, leading to insulin resistance and weight
gain (Figure 7B).
IP7 inhibits Akt by acting at the PH domain of Akt
to prevent its phosphorylation and activation by
PDK1 both in vitro and in vivo. IP7’s regulation of
Akt phosphorylation by PDK1 is selective, as the
catalytic activity of PDK1 toward artificial
substrates is not affected by IP7. IP7 exerts this
action with marked potency, with its IC50 of 20
nM being several orders of magnitude lower than
the IC50 values for other reported actions of inositol
pyrophosphates, such as inhibition of cyclin-CDK
activity by 1/3-IP7 (Lee et al., 2007), and similar to
the Kd (35 nM) for PIP3 binding to the PH domain
of Akt (Currie et al., 1999). Even in the presence
of 1 mM PIP3, the physiologic activator of Akt, IP7
inhibits PDK1’s influences on Akt at equimolarconcentration, comparable to endogenous levels of IP7 (Bennett
et al., 2006). Effects of IP7 are highly selective, with other inositol
phosphates being substantially less potent. The diphosphate in
IP7 differentiates it from IP6 and has been shown to alter the
protonation state of the molecule (Hand and Honek, 2007).
Thus, IP7 binds the clathrin assembly protein AP3 with 5- to
10-fold greater affinity than IP6 (Ye et al., 1995).
The physiologic relevance of these findings is buttressed by
the increased Akt signaling, decreased GSK3b phosphorylation,
and augmented protein translation in IP6K1 knockouts. Phos-
phorylation of GSK3b inhibits its catalytic activity, leading
to increased glycogen levels and reduced adipogenesis97–910, December 10, 2010 ª2010 Elsevier Inc. 905
Figure 6. IP7 Reduces Fat Breakdown and Enhances Adipogenesis
(A) IP6K1 KO mice and WT littermates consume high-fat diets similarly (male, n = 4, each set).
(B–E)Whole-body oxygen consumption (VO2), carbon dioxide release (VCO2), energy expenditure (EE), and respiratory exchange ratio (RER) in IP6K1 KOmice on
control and high-fat diet (male, n = 4, each set). IP6K1 KOmice do not display high-fat diet-induced hypoactivity elicited byWT littermates, resulting in increased
VO2 and EE in the knockouts.
(F and G) Increased fat breakdown in IP6K1 KO mice. Mice on HFD for 25 weeks were switched to regular diet for the indicated time periods. IP6K1 KO mice
display significantly greater decreases in body weight compared to WT littermates (male, n = 3, each set).
(H) Enhancement in IP7 levels during differentiation of NIH 3T3-L1 cells. Inositol phosphate levels were detected in undifferentiated and 3 days postdifferentiated
cells. TNP reduces IP7 levels under both the conditions (n = 3).
(I and J) IP7 regulates adipogenesis through GSK3b pathway. In conjunction, TNP (10 mM) and SB216763 (1 mM) completely block differentiation of NIH 3T3-L1
cells, with minimal effect when treated alone (n = 3).
Each experiment was repeated at least three times. ***p < 0.001; **p < 0.01; *p < 0.05. See also Figure S6.
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Figure 7. Model Depicting Insulin and IP6K1 Regulation of Akt
and Sequelae
(A) Basal signaling. Insulin stimulates IP7 formation. IP7 inhibits Akt activity and
its downstream targets. Akt physiologically stimulates mTOR while inhibiting
GSK3b.
(B) Signaling in insulin resistant tissues. In aging tissues that manifest insulin
resistance, insulin stimulation of IP7 formation is augmented, leading to
pronounced inhibition of Akt, with associated lessening of mTOR activation
and GSK3b inhibition.
Arrows: green, activation; red, inhibition; bold, increased; regular, decreased;
dotted, unknown mechanism. Boxes: large, active; small, less active.(Kaidanovich and Eldar-Finkelman, 2002), predicting that dele-
tion of IP6K1 should lead to insulin hypersensitivity, as observed
in IP6K1 KO mice. Insulin hypersensitivity of IP6K1 KO mice
protects them from the impaired glucose tolerance and hyperin-
sulinemia associated with age or high-fat diet consumption.
Thus, IP7 synthesized by IP6K1 appears to mediate obesityand insulin resistance in mice, at least in part, by inhibiting Akt
and increasing GSK3b activity.
Genetic models of insulin hypersensitivity, such as murine
mutants of protein phosphatase 1B, PPARg, S6K1, and JNK
mutants, are resistant to HFD-induced obesity (Elchebly et al.,
1999; Hirosumi et al., 2002; Izumiya et al., 2008; Jones et al.,
2005; Um et al., 2004). Akt activation is a common feature of
these diverse models of increased insulin sensitivity. These
models support the notion that the sustained insulin sensitivity
of IP6K1 KO mice conveys resistance to weight gain. Both
reduced obesity and increased Akt signaling may elicit the
improved glucose tolerance and insulin sensitivity of the IP6K1
mutants.
Akt has lipogenic effects. Akt 1 and Akt 2 double-knockout
mice display reduced adiposemass and skeletal muscle atrophy
(Peng et al., 2003). Akt 2 deletion in ob/obmice reduces fat accu-
mulation with insulin resistance and hyperglycemia (Leavens
et al., 2009). On the other hand, high-fat diet-induced hepatic
steatosis is correlated with decreased Akt phosphorylation
upon insulin treatment (Pinto Lde et al., 2010). Skeletal muscle-
specific overexpression of Akt 1 reduces fat accumulation while
increasing fatty acid oxidation in the liver with less steatosis (Izu-
miya et al., 2008). Akt/mTOR-mediated skeletal muscle hyper-
trophy (Rommel et al., 2001) leading to increased insulin sensi-
tivity (Izumiya et al., 2008) may be physiologically associated
with the alterations in insulin sensitivity of IP6K1-deleted mice.
Moreover, GSK3b is adipogenic so that its inhibition in IP6K1
mutants may contribute to their leanness (Ross et al., 2000).
Thus, the role of Akt in lipogenesis is complex and may reflect
isoform- and tissue-specific effects.
Overexpression of Akt can be tumorigenic (Manning and
Cantley, 2007). IP6K1 knockouts do not display spontaneous
tumors in their lifetime (data not shown), though we have not
exhaustively explored possible tumorigenicity.
We observe increased IP6K activity in the skeletal muscle of
HFD mice and older mice. Moreover, leptin receptor-deficient
obese ‘‘pound mice’’ display increased IP6K protein levels
(A.C. and S.H.S., unpublished data). These findings are consis-
tent with age-dependent increases in IP7 levels leading to insulin
resistance and obesity.
Our findings imply that selective inhibitors of IP6K1 will have
therapeutic potential in treating type-2 diabetes associated
with obesity and insulin resistance. The risk of adverse effects
from such treatment can be inferred from the phenotype of
IP6K1 knockouts. IP6K1 mutants weigh about 15% less than
controls due to less fat deposition but otherwise appear normal.
Males manifest decreased sperm formation, but potential infer-
tility of males may not represent a major problem in typical
elderly type-2 diabetics.
EXPERIMENTAL PROCEDURES
Detection of Intracellular Inositol Phosphates
The cells were plated at 60% density and incubated with 100 mCi [3H]myoino-
sitol for 3 days. For IGF-1 treatment, on the third day, cells were incubated
overnight with serum-free media containing 100 mCi [3H]myoinositol. The
next morning, cells were harvested after indicated IGF-1 treatment and were
processed for inositol phosphate detection by HPLC. For details, please see
Extended Experimental Procedures.Cell 143, 897–910, December 10, 2010 ª2010 Elsevier Inc. 907
IGF-1, Insulin, and Serum Treatment of Mouse Embryonic
Fibroblasts, Primary Hepatocytes, and HEK293 Cells
Unless otherwise stated, cells were starved overnight and then treated with
media containing one of the following: (1) 10 nM IGF-1, (2) 10% FBS, or (3)
10–20 ng/ml insulin for indicated time periods.
Membrane Isolation
Membrane isolation employed a standard protocol using a Biovision cell
fractionation kit. Caveolin1 or cadherin and lactate dehydrogenase were
used as membrane and cytosolic markers, respectively. Cytosolic contamina-
tion of the membrane preparations were checked by blotting with cytosolic
markers, which showed negative results.
Membrane isolation of TNP-treated HEK293 cells employed the above
protocol after 10 mM TNP treatment of serum-starved cells for indicated time
periods. Cells were fractionated 15 min after IGF-1 treatment.
Enzymatic Synthesis of Radiolabeled IP7 by IP6K1
Purified recombinant 6 3 His-IP6K1 was used in the reaction containing
500 mM cold IP6, 85 nCi of [3H]IP6 (total 83 104 cpm). IP7 was purified based
on standard procedures (Saiardi et al., 2004).
PDK1 Activity Assay on Akt T308 Site In Vitro
Purified recombinant, inactive unphosphorylated Akt at 20 nM final concentra-
tion (unless otherwise stated) was incubated with 100 mM ATP and indicated
concentrations of inositol polyphosphates for 10 min in a reaction buffer
containing 50 mM Tris, 100 mM NaCl, and 1 mM DTT. PDK1, final concentra-
tion 20 nM, was added, and themixture incubated at 30C for 30min. Samples
were then boiled with LDS buffer, run on SDS-PAGE, and detected with
a-p-T308 antibody. Bands were quantified using ImageJ software. Data
from three independent experiments were plotted using Sigmaplot software.
Details are in Extended Experimental Procedures.
Metabolic Measurements
Metabolic parameters were measured in 10-month-old mice ad libitum fed or
4 hr/16 hr fasted mice. Blood glucose levels were measured from tail vein
bleedings of mice using an Ascensia Contour blood glucose meter and test
strips (Bayer). Ultrasensitive mouse insulin ELISA kit (Alpco Diagnostics) and
mouse leptin ELISA kit (Millipore) were used to measure insulin and leptin,
respectively.
Glucose tolerance test (GTT) was performed on 16 hr fasted mice injected
i.p. with D-glucose (2 g/kg body weight). Blood glucose level was monitored
by tail bleeding immediately before and at indicated time points after injection
(Bhandari et al., 2008). For insulin tolerance tests, mice were fasted 4 hr and
were given 0.75 units/kg body weight human recombinant insulin (Invitrogen)
i.p. Blood glucose measurements were obtained from tail veins at indicated
time points postinjection (Bhandari et al., 2008).
Hyperinsulinemic-Euglycemic Clamp Study and Tissue Glucose
Uptake Analysis
Ten-month-old mice were used in the study. Details are in Extended Experi-
mental Procedures.
Acute Insulin Treatment in Mice
Ten-month-old mice, after 4 hr fast, were anaesthetized, and 25 mU/kg insulin
(Invitrogen) or equal volumes of vehicle were administered through the portal
vein. Gastrocnemius muscle, epididymal white adipose tissue (EWAT), and
liver were collected 120 s after the injection and immediately stored in liquid
nitrogen. Protein extracts from the tissue samples were prepared and run on
SDS-PAGE. For detection of tyrosine phosphorylation on IRS1, IRS1 was
immunoprecipitated from 1 mg total cell lysate and was blotted with a-p-tyro-
sine and a-IRS1 antibody.
Indirect Calorimetry
Indirect calorimetry was conducted in an open-flow indirect calorimeter
(Oxymax Equal Flow System; Columbus Instruments, Columbus, OH) at the
Center for Metabolism and Obesity Research (Johns Hopkins University
School of Medicine). Energy expenditure (EE) was calculated based on total908 Cell 143, 897–910, December 10, 2010 ª2010 Elsevier Inc.bodymass (fat mass + leanmass) (Kaiyala et al., 2010). Details are in Extended
Experimental Procedures.
Adipocyte Differentiation Studies
NIH 3T3-L1 preadipocyte cells were cultured and differentiated following
standard protocol (ZenBio). In brief, preadipocytes were maintained in preadi-
pocyte media (PM-1-L1) differentiated for 3 days with differentiation media
(DM-2-L1). After 3 days of differentiation, cells were maintained for another 7
days in adipocyte maintenance media (AM-1-L1). See details in Extended
Experimental Procedures.
Statistical Analysis
All results are presented as the mean and standard error of at least three
independent experiments. Statistical significance was calculated by Student’s
t test using the Sigmaplot software (***p < 0.001; **p < 0.01; *p < 0.05).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at doi:10.1016/j.cell.
2010.11.032.
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